Perspective - Journal of Cell Biology and Metabolism (2024) Volume 6, Issue 3
Exploring Cell Therapy: Revolutionizing Modern Medicine
Jiajun Zhu*Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, USA.
- *Corresponding Author:
- Jiajun Zhu
Department of Cancer Biology and Genetics
Memorial Sloan Kettering Cancer Center, New York, USA.
E-mail: Zhu@mskcc.org
Received: 04-Jun-2024, Manuscript No. AACBM-24-138758; Editor assigned: 06-Jun-2024, PreQC No. AACBM-24-1387585(PQ); Reviewed: 20-Jun-2024, QC No AACBM-24-1387585; Revised: 22-Jun-2024, Manuscript No. AACBM-24-1387585(R); Published: 28-Jun-2024, DOI:10.35841/aacbm-6.3.209
Citation: Zhu J. Exploring cell therapy: Revolutionizing modern medicine. J Cell Biol Metab. 2024;6(3):209.
Introduction
Cell therapy is an innovative and rapidly advancing field in modern medicine that uses living cells to repair or replace damaged tissues and treat various diseases. It holds the potential to revolutionize healthcare by offering new treatments for conditions that are currently difficult or impossible to cure. This article explores the principles, types, applications, and future prospects of cell therapy, highlighting its transformative impact on medicine [1].
Understanding cell therapy
Cell therapy involves the administration of live cells to a patient to treat disease or repair tissue damage. These cells can originate from the patient (autologous cells), a donor (allogeneic cells), or be derived from other sources such as stem cells or genetically engineered cells [2].
Stem cell therapy
Stem cells are undifferentiated cells with the ability to develop into different cell types. They can be harvested from various sources, including [3]. Derived from early-stage embryos, these cells can differentiate into any cell type in the body. Found in specific tissues like bone marrow, these cells have a more limited differentiation potential but are less controversial than ESCs. Hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are common examples [4].
Generated by reprogramming adult cells to a pluripotent state, iPSCs can differentiate into any cell type and bypass ethical concerns associated with ESCs. Chimeric Antigen Receptor (CAR) T-Cell Therapy: T-cells are genetically engineered to express receptors that recognize and attack cancer cells. Tumor-Infiltrating Lymphocytes (TIL) Therapy: T-cells isolated from a patient's tumor are expanded and activated in the lab before being reintroduced to target cancer cells [5].
Gene editing technologies, such as CRISPR-Cas9, allow precise modifications of the genome within cells. This approach can correct genetic defects, enhance cell function, or confer new properties to cells used in therapy [6].
Cancer treatment
Has shown remarkable success in treating certain types of blood cancers, such as leukemia and lymphoma, by specifically targeting and killing cancer cells. Dendritic cells are engineered to present tumor antigens, stimulating an immune response against cancer [7].
Hematopoietic Stem Cell Transplantation (HSCT): Used to reset the immune system in patients with severe autoimmune diseases like multiple sclerosis and lupus [8].
Challenges and future prospects
Ensuring the safety and effectiveness of cell-based treatments is crucial. Potential risks include immune rejection, uncontrolled cell growth, and tumor formation [9]. The use of embryonic stem cells and genetic modifications raises ethical concerns and requires stringent regulatory oversight. Producing and scaling up cell therapies to meet clinical demand is complex and expensive [10].
Conclusion
Cell therapy represents a groundbreaking approach in modern medicine, offering hope for treating a wide range of diseases and injuries that were once considered incurable. By harnessing the power of living cells, this field has the potential to transform healthcare, improve patient outcomes, and pave the way for a new era of regenerative medicine. As research and technology continue to evolve, cell therapy will undoubtedly play an increasingly prominent role in the future of medical treatment.
References
- Strauer BE, Kornowski R. Stem cell therapy in perspective. Circulation. 2003;107(7):929-34.
- Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451(7181):937-42.
- Biehl JK, Russell B. Introduction to stem cell therapy. J Cardiovasc Nurs. 2009;24(2):98-103.
- Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372-85.
- Lindvall O, Björklund A. Cell therapy in Parkinson’s disease. NeuroRx. 2004;1:382-93.
- Kim SU, De Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J Neurosci Res. 2009;87(10):2183-200.
- Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34(4):393-400.
- Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243-65.
- Wollert KC, Drexler H. Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol. 2010;7(4):204-15.
- Malliaras K, Marban E. Cardiac cell therapy: where we've been, where we are, and where we should be headed. Br Med Bull. 2011;98(1):161-85.
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref
Indexed at, Google Scholar, Cross Ref